Your browser doesn't support javascript.
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
Bhalla, Sheena; Bakouny, Ziad; Schmidt, Andrew L; Labaki, Chris; Steinharter, John A; Tremblay, Douglas A; Awad, Mark M; Kessler, Alaina J; Haddad, Robert I; Evans, Michelle; Busser, Fiona; Wotman, Michael; Curran, Catherine R; Zimmerman, Brittney S; Bouchard, Gabrielle; Jun, Tomi; Nuzzo, Pier V; Qin, Qian; Hirsch, Laure; Feld, Jonathan; Kelleher, Kaitlin M; Seidman, Danielle; Huang, Hsin-Hui; Anderson-Keightly, Heather M; El Zarif, Talal; Abou Alaiwi, Sarah; Rosenbloom, Talia D; Stewart, Penina S; Galsky, Matthew D; Choueiri, Toni K; Doroshow, Deborah B.
  • Bhalla S; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Bakouny Z; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Schmidt AL; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Labaki C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Steinharter JA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Tremblay DA; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Awad MM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Kessler AJ; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Haddad RI; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Evans M; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Busser F; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Wotman M; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Curran CR; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Zimmerman BS; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Bouchard G; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Jun T; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Nuzzo PV; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Qin Q; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Hirsch L; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Feld J; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Kelleher KM; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Seidman D; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Huang HH; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Anderson-Keightly HM; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • El Zarif T; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Abou Alaiwi S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Rosenbloom TD; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Stewart PS; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Galsky MD; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
  • Choueiri TK; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Doroshow DB; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. Electronic address: deborah.doroshow@mssm.edu.
Lung Cancer ; 160: 78-83, 2021 10.
Article in English | MEDLINE | ID: covidwho-1313324
ABSTRACT

INTRODUCTION:

Patients with lung cancer (LC) are susceptible to severe outcomes from COVID-19. This study evaluated disruption to care of patients with LC during the COVID-19 pandemic.

METHODS:

The COVID-19 and Cancer Outcomes Study (CCOS) is a prospective cohort study comprised of patients with a current or past history of hematological or solid malignancies with outpatient visits between March 2 and March 6, 2020, at two academic cancer centers in the Northeastern United States (US). Data was collected for the three months prior to the index week (baseline period) and the following three months (pandemic period).

RESULTS:

313 of 2365 patients had LC, 1578 had other solid tumors, and 474 had hematological malignancies. Patients with LC were not at increased risk of COVID-19 diagnosis compared to patients with other solid or hematological malignancies. When comparing data from the pandemic period to the baseline period, patients with LC were more likely to have a decrease in in-person visits compared to patients with other solid tumors (aOR 1.94; 95% CI, 1.46-2.58), but without an increase in telehealth visits (aOR 1.13; 95% CI 0.85-1.50). Patients with LC were more likely to experience pandemic-related treatment delays than patients with other solid tumors (aOR 1.80; 95% CI 1.13-2.80) and were more likely to experience imaging/diagnostic procedure delays than patients with other solid tumors (aOR 2.59; 95% CI, 1.46-4.47) and hematological malignancies (aOR 2.01; 95% CI, 1.02-3.93). Among patients on systemic therapy, patients with LC were also at increased risk for decreased in-person visits and increased treatment delays compared to those with other solid tumors.

DISCUSSION:

Patients with LC experienced increased cancer care disruption compared to patients with other malignancies during the early phase of the COVID-19 pandemic. Focused efforts to ensure continuity of care for this patient population are warranted.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Lung Cancer Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: J.lungcan.2021.07.002

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Lung Cancer Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: J.lungcan.2021.07.002